Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer
Chen,N.,Wang,Z.,Chen,M.,Ma,Q.,He,Y.,Wang,Y.,Li,X.,Qiu,M.,Shi,L.,Zhu,S.,Xie,Q.,Liu,X.,Shi,B.,Lin,G.,Yang,W.,Liao,Y.,Zhang,H.,Wang,S.,Li,J.,Wang,S.,Dong,L.,Chen,H.,Lu,J.,Cheng,Y.,Zhang,X.,Ma,L.,Zhou,L.,Wang,H.,Li,S.,Ye,D.
DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0335
2024-02-06
Cancer Biology and Medicine
Abstract:Objective: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients. Methods: This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone <50 ng/dL), and goserelin safety. The exploratory outcome was the monitoring pattern for serum testosterone and PSA. All analyses were descriptive. Results: Between September 2017 and December 2019, a total of 294 eligible patients received ≥ 1 dose of goserelin; 287 patients (97.6%) were treated with goserelin 10.8-mg depot. At week 24 ± 2, the changes from baseline [standard deviation (95% confidence interval)] in serum testosterone ( n = 99) and PSA ( n = 131) were –401.0 ng/dL [308.4 ng/dL (–462.5, –339.5 ng/dL)] and –35.4 ng/mL [104.4 ng/mL (–53.5, –17.4 ng/mL)], respectively. Of 112 evaluable patients, 100 (90.2%) achieved a serum testosterone level < 50 ng/dL. Treatment-emergent adverse events (TEAEs) and severe TEAEs occurred in 37.1% and 10.2% of patients, respectively. The mean testing frequency (standard deviation) was 1.6 (1.5) for testosterone and 2.2 (1.6) for PSA. Conclusions: Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.
oncology,medicine, research & experimental